Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $67.80 million which beat the analyst consensus estimate of $66.82 million by 1.47 percent. This is a 6.75 percent increase over sales of $63.51 million the same period last year.
Amazon, Meta, and Google: Analysts Reveal Unseen Insights for 2024
Wedbush analysts led by Scott Devitt painted their internet outlook for 2024.
Looking ahead to 2024, the analysts noted that leading consumer internet platforms remain well positioned with rising margins and improving industry growth rates across eCommerce and digital advertising.
